{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:51Z","timestamp":1783024071811,"version":"3.54.6"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    A 49-year-old man diagnosed with well-differentiated adenocarcinoma of the colon, along with liver metastases, underwent several treatments, including chemotherapy, laparoscopic colostomy, and radiofrequency ablation. After receiving a liver transplant, he achieved 1-year disease-free status. However, rising serum levels of carcinoembryonic antigen (CEA) led to further evaluation, which revealed new metastases in the liver and lungs. As a last resort, he was treated with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 radioligand therapy, but the biochemical response was disappointing, as CEA levels continued to rise. Tragically, the patient experienced respiratory decompensation and passed away 10 weeks after the treatment. This case underscores the potential of FAP-targeted radioligand therapy in managing advanced colon cancer and suggests that earlier intervention might be beneficial.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006230","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:00:24Z","timestamp":1775491224000},"page":"e613-e616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Experience With 177Lu-FAPI-2286 Therapy as the Last Resort in a Patient With Metastatic Colon Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Amin","family":"Saber Tanha","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Raeisi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Zahed Anaraki","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Mashhad University of Medical Sciences, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Kamali","sequence":"additional","affiliation":[{"name":"Department of Radiopharmaceuticals Diagnostic and Theranostic Kits Products, Pars Isotope Co, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1097\/RLU.0000000000005753","article-title":"Favorable palliative effect of 177Lu-FAPI-2286 in two breast cancer patients with refractory bone pains","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy With 177Lu-FAPI-2286 and tyrosine kinase inhibitor: a novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/RLU.0000000000005728","article-title":"177Lu-FAPI-2286 therapy in a patient with radio-iodine refractory papillary thyroid carcinoma: a favorable clinical and biochemical response","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0000000000005168","article-title":"177Lu-FAP-2286 therapy in a metastatic bone malignant solitary fibrous tumor","volume":"49","author":"Yang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","article-title":"First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma","volume":"49","author":"Banihashemian","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/RLU.0000000000004260","article-title":"FAP-targeted radionuclide therapy of advanced radioiodine-refractory differentiated thyroid cancer with multiple cycles of 177Lu-FAPI-46","volume":"47","author":"Fu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"12","key":"R8-20260702","first-page":"1917","article-title":"Feasibility, tolerability, and preliminary clinical response of fractionated radiopharmaceutical therapy with 213 Bi-FAPI-46: pilot experience in patients with end-stage, progressive metastatic tumors","volume":"65","author":"Helisch","year":"2024","journal-title":"J Nucl Med"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu\u2013fibroblast activation protein inhibitor\u201346 for patients with relapsed or refractory cancers","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: a systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:13Z","timestamp":1783023013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006230","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"2025-07-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}